The Safety, Immunogenicity, and Acceptability of Inactivated Influenza Vaccine Delivered by Microneedle Patch (TIV-MNP 2015): A Randomised, Partly Blinded, Placebo-controlled, Phase 1 Trial

Authors

Nadine G. Rouphael, Emory UniversityFollow
Michele Paine, Emory University
Regina Mosley, Emory University
Sebastien Henry, Emory University
Devin V. McAllister, Georgia Institute of Technology
Haripriya Kalluri, Georgia Institute of Technology
Winston Pewin, Georgia Institute of Technology
Paula M. Frew, University of Nevada, Las VegasFollow
Tianwei Yu, Emory University
Natalie J. Thornburg, Emory University
Sarah Kabbani, Emory University
Lilin Lai, Emory University
Elena V/ Vassilieva, Emory University
Ioanna Skountzou, Emory University
Richard W. Compans, Emory University
Mark J. Mulligan, Emory University
Mark R. Prausnitz, Georgia Institute of Technology

Document Type

Article

Publication Date

6-27-2017

Publication Title

The Lancet

Volume

390

Issue

10095

First page number:

649

Last page number:

658

Abstract

Background

Disciplines

Public Health

Language

English

Repository Citation

Rouphael, N. G., Paine, M., Mosley, R., Henry, S., McAllister, D. V., Kalluri, H., Pewin, W., Frew, P. M., Yu, T., Thornburg, N. J., Kabbani, S., Lai, L., Vassilieva, E. V., Skountzou, I., Compans, R. W., Mulligan, M. J., Prausnitz, M. R. (2017). The Safety, Immunogenicity, and Acceptability of Inactivated Influenza Vaccine Delivered by Microneedle Patch (TIV-MNP 2015): A Randomised, Partly Blinded, Placebo-controlled, Phase 1 Trial. The Lancet, 390(10095), 649-658.
http://dx.doi.org/10.1016/S0140-6736(17)30575-5